Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 29, 2019
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Sept. 29, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced final results from the full...
-
Sep 27, 2019Analysis of 12-month data from Phase 3 SUNRISE 2 assessed the long-term effectiveness and safety of lemborexant in adults with insomnia
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced new effectiveness and safety data from the Phase 3 clinical development program for lemborexant, an...
-
Sep 24, 2019Insomnia or Sleeping Difficulties Negatively Impact Household Cohabitants in Unexpected Ways
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from its company-sponsored survey, titled "How America Sleeps and Wakes," was presented at the 2019...
Sep 24, 2019- Data includes an oral presentation from full advanced endometrial carcinoma (EC) cohort of Phase 1b/2 study of KEYTRUDA plus LENVIMAEisai today announced the presentation of new data and analyses via one oral proffered paper presentation, four poster discussions and seven poster presentations at the 2019 European Society for...
-
Sep 19, 2019Oral Presentation about Results from First Phase 3 Head-to-Head Study with Pre-specified Endpoints vs. Zolpidem ER (SUNRISE 1)
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that new long-term, Phase 3 data and additional analyses of lemborexant will be highlighted in eight...